Corticosteroid-sparing effects of risankizumab efficacy and safety in patients with moderately to severely active ulcerative colitis
J Crohns Colitis. 2025;19(4):jjaf025 doi: 10.1093/ecco-jcc/jjaf025
Reinisch W, et al. report that the efficacy of RZB induction therapy is independent of CS use, with high rates of CS-free outcomes observed in the overall population and among patients with baseline CS use.
This analysis utilised data from Phase 3 INSPIRE and COMMAND studies and evaluated the CS-sparing effects of RZB in patients with moderate-to-severe UC. Results reaffirm the potential of RZB to serve as a CS-sparing therapy for patients with UC.
Keywords:
